Search Results sclc cells
1.
New York Inventor Develops Small Cell Lung Cancer Treatment Method
...cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful...targets for detecting, diagnosing, inhibiting or killing SCLC cells." The inventor was issued U.S. Patent No. 7,435,415 on...
October 20, 2008; US Fed News Service, Including US State News
2.
Inventor Develops Small Cell Lung Cancer Detection Monoclonal Antibodies
...cell surface antigens found on small cell lung cancer (SCLC) cells." An abstract of the invention, released by the Patent...targets for detecting, diagnosing, inhibiting or killing SCLC cells." The inventor was issued U.S. Patent No. 7,183,389 on...
March 8, 2007; US Fed News Service, Including US State News
3.
ImmunoGen Compound Eradicates Human Small-Cell Lung Cancer Tumors in Mice
...antigen-specific cytotoxicity against cultured SCLC cells. Administration of 300 micrograms...eradicated transplanted tumors of human SCLC cells in all mice, with no tumor recurrence...to CD56, a marker expressed on all SCLC cells. hN901-DM1 is able to harness the...
April 14, 1997; PR Newswire
4.
British Biotech and ImmunoGen Begin Patient Enrollment for the Phase I/II Trial of BB-10901/huN901-DM1 in Small Cell Lung Cancer.
...DM1, a maytansinoid, with the humanized monoclonal antibody, huN901, which binds to a protein found on the surface of SCLC cells. In preclinical studies, BB-10901 eradicated SCLC tumors. Under the same experimental conditions, other chemotherapies...
May 29, 2001; PR Newswire
5.
U.S. Patents Awarded to Inventors in New York (Oct. 20)
...immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis...can serve as targets for detecting, diagnosing, inhibiting or killing SCLC cells."The inve
October 20, 2008; Targeted News Service
6.
Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update.
...Announced at the AACR Annual Meeting expanded preclinical data indicating that picoplatin retained its anti-tumor activity in SCLC cells resistant to previous treatment with cisplatin, carboplatin or oxaliplatin. These data support the property of picoplatin...
July 31, 2008; PR Newswire
7.
British Biotech in collaboration with ImmunoGen to develop and commercialize huN901-DM1 for the treatment of small cell lung cancer.
...targeted by the monoclonal antibody. huN901-DM1 is a TAP consisting of a humanized monoclonal antibody (huN901) targeting SCLC cells, coupled with a highly potent cytotoxic agent (DM1), a maytansine derivative. In preclinical studies, huN901-DM1 eradicated...
May 5, 2000; Business Wire
8.
The Lipid-Associated 3D Structure of SPA, a Broad-Spectrum Neuropeptide Antagonist with Anticancer Properties
...SpD), and [D-Arg^sup 1^, D-Trp^sup 5,7,9^, Leu^sup 11^] substance P (SPA)) have been shown to inhibit the growth of SCLC cells in vivo and in vitro (4,5). In initial studies, these broad-spectrum neuropeptide antagonists were shown to be competitive...
December 15, 2006; Biophysical Journal
9.
ImmunoGen, Inc. and British Biotech plc Enter Collaboration to Develop and Commercialize huN901-DM1 for the Treatment of Small-Cell Lung Cancer.
...huN901-DM1. huN901-DM1 is a tumor-activated prodrug consisting of a humanized monoclonal antibody (huN901) targeting SCLC cells, coupled with a highly potent cytotoxic agent (DM1), a maytansine derivative. In preclinical studies, huN901-DM1 eradicated...
May 5, 2000; PR Newswire
10.
Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial.
...not only found it difficult to obtain picoplatin resistant cells but also found that picoplatin remained effective in SCLC cells previously treated with the other platinum agents. According to Dr. De Jager, The data supports the possible use of picoplatin...
April 13, 2008; PR Newswire
|
